The stock of T2 Biosystems Inc (NASDAQ:TTOO) is a huge mover today! The stock increased 7.53% or $0.42 during the last trading session, hitting $6. About 66,239 shares traded hands. T2 Biosystems Inc (NASDAQ:TTOO) has declined 41.20% since April 5, 2016 and is downtrending. It has underperformed by 43.16% the S&P500.
The move comes after 6 months positive chart setup for the $146.19 million company. It was reported on Nov, 7 by Barchart.com. We have $12.18 PT which if reached, will make NASDAQ:TTOO worth $150.58 million more.
T2 Biosystems Inc (NASDAQ:TTOO) Ratings Coverage
Out of 7 analysts covering T2 Biosystems Inc (NASDAQ:TTOO), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. T2 Biosystems Inc has been the topic of 12 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm earned “Hold” rating on Sunday, August 16 by BTIG Research. The stock has “Neutral” rating given by BTIG Research on Tuesday, July 21. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, November 2 report. BTIG Research upgraded T2 Biosystems Inc (NASDAQ:TTOO) on Thursday, September 3 to “Buy” rating. The stock of T2 Biosystems Inc (NASDAQ:TTOO) earned “Buy” rating by Canaccord Genuity on Tuesday, October 27. On Wednesday, July 20 the stock rating was upgraded by WBB Securities to “Strong Buy”. The firm has “Buy” rating given on Tuesday, August 2 by Canaccord Genuity. The stock has “Neutral” rating given by Janney Capital on Tuesday, April 12.
According to Zacks Investment Research, “T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts.”
More important recent T2 Biosystems Inc (NASDAQ:TTOO) news were published by: Marketwatch.com which released: “T2 Biosystems stock price target cut to $11 from $13 at Leerink Partners” on August 07, 2014, also Prnewswire.com published article titled: “Canon U.S.A. Announces Equity Investment in T2 Biosystems, Inc.”, Quotes.Wsj.com published: “News T2 Biosystems Inc.TTOO” on August 01, 2014. More interesting news about T2 Biosystems Inc (NASDAQ:TTOO) was released by: Benzinga.com and their article: “T2 Biosystems Cut From Buy To Sell At BTIG” with publication date: July 08, 2016.
TTOO Company Profile
T2 Biosystems, Inc., incorporated on April 27, 2006, is an in vitro diagnostics firm that is engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Firm is focused on developing and launching commercially its diagnostic products aimed at reducing mortality rates, improving patient outcomes and reducing the cost of healthcare. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance approach that measures how water molecules react in the presence of magnetic fields. The Company’s platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.